MORGAN STANLEY PLC/CALL/MADRIGAL PHARMACEUTICALS/275/0.02/20.12.24

MORGAN STANLEY PLC/CALL/MADRIGAL PHARMACEUTICALS/275/0.02/20.12.24 Share Price

DE000ME9H247

Real-time Bid/Ask 10:14:54 16/07/2024 pm IST
0.98 ^EUR / 1.08 ^EUR	+6.19%

Current month	-3.96%
1 month	-3.00%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart MADRIGAL PHARMACEUTICALS, INC.

Chart MORGAN STANLEY PLC/CALL/MADRIGAL PHARMACEUTICALS/275/0.02/20.12.24

Latest news about MADRIGAL PHARMACEUTICALS, INC.

JMP Securities Raises Price Target on Madrigal Pharmaceuticals to $385 From $381, Maintains Market Outperform Rating	08:47pm	MT
Non Alcoholic Fatty Liver Disease Pipeline 2024 \| Guangdong Raynovent Biotech, Dr. Falk Pharma GmbH, Enyo Pharma, Viking Therapeutics, Sagimet Biosciences, Terns, Sinew Pharma, Madrigal Pharmaceutical	10/07	AQ
Cantor Fitzgerald Starts Madrigal Pharmaceuticals With Neutral Rating	28/06	MT
Transcript : Madrigal Pharmaceuticals, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 08:40 AM	11/06

More news

Quotes 5-day view

Date	Price	Change
16/24/16	0.98	+1.03%
15/24/15	0.97	-7.62%
12/24/12	1.05	-6.25%
11/24/11	1.12	+0.90%
10/24/10	1.11	-4.31%

Delayed Quote Börse Stuttgart

Last update July 16, 2024 at 09:02 pm IST

More quotes

Static data

Product type	Warrants
Buy / Sell	CALL
Underlying	MADRIGAL PHARMACEUTICALS, INC.
Issuer	Morgan Stanley
WKN	ME9H24
ISIN	DE000ME9H247
Date issued	01/03/2024
Strike	275 $
Maturity	20/12/2024 (157 Days)
Parity	50 : 1
Emission price	1.21 €
Emission volume	N/A
Settlement	règlement en espèces
Currency	EUR

Technical Indicators

Highest since issue	1.91 €
Lowest since issue	0.31 €
Delta	0.62x
Omega	3.102
Premium	19.01x
Gearing	5x
Moneyness	1.010
Difference Strike	-3.955 $
Difference Strike %	-1.44%
Spread	0.1 €
Spread %	9.35%
Theoretical value	1.010
Implied Volatility	71.85 %
Total Loss Probability	56.84 %
Intrinsic value	0.0334
Present value	0.9766
Break even	329.97 €
Theta	-0.02x
Vega	0.01x
Rho	0.01x

Company Profile

Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH). The Company's product candidate, resmetirom, is a once-daily, oral, liver-directed thyroid hormone receptor-Î² (THR-Î²) agonist designed to target key underlying causes of NASH. NASH is a more advanced form of non-alcoholic fatty liver disease (NAFLD). The Companyâs clinical development program includes MAESTRO-NASH, MAESTRO-NAFLD-1, and MAESTRO-NASH OUTCOMES.

Sector

More about the company

Consensus: Madrigal Pharmaceuticals, Inc.

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

280 USD

Average target price

365.3 USD

Spread / Average Target

+30.50%

Consensus